Lewes, DE -- (SBWIRE) -- 10/02/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Steel Dynamics, Inc. (NASDAQ:STLD), Immunomedics, Inc. (NASDAQ:IMMU), Novavax, Inc. (NASDAQ:NVAX), Prospect Capital Corporation (NASDAQ:PSEC).
Steel Dynamics, Inc. (NASDAQ:STLD), increased1.26% and closed at $16.93 on a traded volume of 3.27 million shares, in comparison to 2.08 million shares of average trading volume. So far this year, the stock is up over 23.31%.
The company has a total market capitalization of $3.74Billion and its total outstanding shares are 220.80 million.
Will STLD Continue To Move Higher? Find Out Here
Steel Dynamics, Inc., together with its subsidiaries, produces and sells steel products in the United States and internationally. The company operates in three segments: Steel Operations, Metals Recycling and Ferrous Resources Operations, and Steel Fabrication Operations.
Immunomedics, Inc. (NASDAQ:IMMU), soared9.84% and closed at $6.81 on a traded volume of 3.22 million shares, whereas its average trading volume is 975,330 shares. In the last three months, the stock is up24.04%. The Intra-day range for the stock is $6.30 and $6.81.
For How Long IMMU’s Gloss will Attract Investors? Find out via this report
Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases.
Novavax, Inc. (NASDAQ:NVAX), jumped up0.95 % and closed at $3.18. So far in three months, the stock is up 50.71%. The 52-week range for the stock is $1.52 and $3.50 and during the previous trading session it marked$3.23 as its highest price. The stock initially exchanged hands with a price of $3.16 and the overall traded volume that day was 3.20million shares.
Will NVAX Continue To Move Higher? Find Out Here
Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company’s technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines.
Prospect Capital Corporation (NASDAQ:PSEC) after opening its shares at the price of $11.14, jumped up0.36% to close the day at $11.21. The stock ended on a traded volume of 3.17 million shares, in comparison to 3.34 million shares of average trading volume. The 52-week range for the stock is $9.80 and $11.98 and during the previous trading session the stock scored the highest price of $11.23. It started the day at $11.14.
Why Should Investors Buy PSEC After The Recent Gain? Just Go Here and Find Out.
Prospect Capital Corporation is a business development company. It specializes in middle market, mature, mezzanine finance, later stage, emerging growth, buyouts, recapitalizations, turnaround, growth capital, development, cash flow term loans, and bridge transactions.
About LeadingStockAlerts:
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
Disclaimer:
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/